Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-22T23:49:27.105Z Has data issue: false hasContentIssue false
  • English
  • Français

Pandemic Influenza: Antiviral Preparedness and Health Care Workers

Published online by Cambridge University Press:  08 April 2013

Ruth B. Schneider ,
John G. Benitez ,
Anne D’Angelo  and
Kathee Tyo
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The primary objective of this study was to determine the preparedness for pandemic influenza of hospitals, in terms of amount of antiviral drugs on hand and employee vaccination rates, in the Finger Lakes region (FLR) of western New York.

Methods: A survey of the 17 FLR hospitals was conducted via e-mail during the period of June 2007 to August 2007.

Results: A total of 13 of 17 hospitals responded for a response rate of 76.5%. Only 23.1% of responding hospitals stockpile antiviral drugs. Vaccination rates for personnel with patient contact ranged from 36.8% to 76.1%.

Conclusions: Hospitals in the FLR have insufficient quantities of antiviral agents stockpiled to provide for the protection of health care workers, and influenza vaccination rates for health care workers are low. To ensure that a high level of care is maintained during a pandemic, health care workers need to be provided with appropriate protection. This can be accomplished if hospitals stockpile antiviral agents designated for the treatment and prophylaxis of health care workers with patient contact and their families.

(Disaster Med Public Health Preparedness. 2010;4:55-61)

Keywords

pandemicsantiviral agentsvaccination ratesstockpilingdisease outbreaksinfluenzahealth personnelhospitalsdisaster preparednessNew Yorkdrug utilization
Type
Original Articles
Information
Disaster Medicine and Public Health Preparedness , Volume 4 , Issue 1 , March 2010 , pp. 55 - 61
Copyright
Copyright © Society for Disaster Medicine and Public Health, Inc. 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Johnson, NPAS, Mueller, J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76:105–115.CrossRefGoogle ScholarPubMed
2.Glezen, WP. Emerging infections: pandemic influenza. Epidemiol Rev. 1996;18:64–76.CrossRefGoogle ScholarPubMed
3.Taubenberger, JK, Morens, DM. 1918 influenza: the mother of all pandemics Emerg Infect Dis.2006. http://www.cdc.gov/NCIDOD/EID/vol12no01/05-0979.htm. Accessed December 28, 2009.Google Scholar
4.World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO 23 March 2009. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_03_23a/en/index.html.Accessed March 28, 2009.Google Scholar
5.Meltzer, MI, Cox, NJ, Fukuda, K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–671.Google Scholar
6.Hayden, FG. Perspectives on antiviral use during pandemic influenza. Phil Trans R Soc Lond. 2001;356:1877–1884.Google Scholar
7.American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. Pediatrics. 2007;119:852–860.Google Scholar
8.Englund, JA, Champlin, RE, Wyde, PR. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998;26:1418–1424.Google Scholar
9.Moscona, A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363–1373.Google Scholar
10.Monto, AS, Webster, A, Keene, O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44:23–29.Google Scholar
11.Treanor, JJ, Hayden, FG, Vrooman, PS. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000;238:1016–1024.Google Scholar
12.Cooper, NJ, Sutton, AJ, Abrams, KR. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized trials. BMJ. 2003;326:1235.Google Scholar
13.Kaiser, L, Wat, C, Mills, T. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–1672.Google Scholar
14.Carr, J, Ives, J, Kelly, L. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vitro. Antiviral Res. 2002;54:79–88.Google Scholar
15.Ives, JA, Carr, JA, Mendel, DB. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307–317.Google Scholar
16.Centers for Disease Control and Prevention. CDC Issues Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance Among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season.December 19, 2008. http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum_00279. Accessed March 23, 2009.Google Scholar
17.Hayden, FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 2006;71:372–378.Google Scholar
18.Simeonsson, K, Summers-Bean, C, Connolly, A. Influenza vaccination of healthcare workers: institutional strategies for improving rates. N C Med J. 2004;65:323–329.Google Scholar
19.Leavitt, MO. Pandemic Planning Update VI.January 8, 2009. http://www.flu.gov/professional/pdf/panflureport6.pdf. Accessed December 28, 2009.Google Scholar
20.Homeland Security Council. National Strategy for Pandemic Influenza: Implementation Plan One Year SummaryJuly 2007. http://www.flu.gov/professional/federal/pandemic-influenza-oneyear.pdf. Accessed December 17, 2009.Google Scholar
21.Gerdil, C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776–1779.Google Scholar
22.US Department of Health and Human Services, US Department of Homeland Security. Guidance on Allocating and Targeting Pandemic Influenza Vaccine. http://www.pandemicflu.gov/vaccine/allocationguidance.pdf. Accessed March 23, 2009.Google Scholar
23.US Department of Health and Human Services. Guidance on Antiviral Drug Use During an Influenza Pandemic. http://www.pandemicflu.gov/vaccine/antiviral_use.html. Accessed March 23, 2009.Google Scholar
24.US Department of Health and Human Services. Antivirals–State Allocations. http://www.pandemicflu.gov/plan/states/antivirals.html. Accessed March 23, 2009.Google Scholar
25.Homeland Security Council. Implementation plan for the national strategy for pandemic influenza.2006; p 8. http://georgewbushwhitehouse.archives.gov/homeland/pandemic-influenza-implementation.html. Accessed December 28, 2009.Google Scholar
26.Bullard, WM. NYSDOH Teleconference. Pandemic Influenza Update. July 27, 2007.Google Scholar
27.Birkhead, G. NYSDOH Statewide Videoconference. Allocation of Ventilators in an Influenza Pandemic. March 16, 2007.Google Scholar
28.American College of Physicians. The health care response to pandemic influenza. Ann Intern Med. 2006;145:135–137.Google Scholar
Center Comments. Comments from the Center for Biosecurity of UPMC on Draft Guidelines for Pandemic Influenza Planning. Biosecur Bioterrorism: Biodefense Strat Pract Sci. 2008;6:279-284.Google Scholar
29.US Department of Health and Human Services. Consideration for Antiviral Drug Stockpiling by Employers in Preparation for an Influenza Pandemic. http://www.pandemicflu.gov/vaccine/antiviral_employers.html. Accessed March 23, 2009.Google Scholar
31.Emmanuel, EJ. The lessons of SARS. Ann Intern Med. 2003;139:589–591.Google Scholar
32.Qureshi, K, Gerson, RR, Sherman, MF. Health care workers' ability and willingness to report to duty during catastrophic disasters. J Urban Health. 2005;82:378–388.Google Scholar
33.Syrett, JI, Benitez, JG, Livingston, WH 3rd, Davis, EA. Will emergency health care providers respond to mass casualty incidents? Prehosp Emerg Care. 2007;11:49–54.Google Scholar
34.Gardam, M, Liang, D, Moghadas, SM. The impact of prophylaxis of healthcare workers on influenza pandemic burden. J R Soc Interface. 2007;4:727–734.Google Scholar
35.Cinti, S, Cheoweth, C, Monto, AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol. 2005;26:852–854.Google Scholar